Login
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc

ligand.com

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 47 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Financial Snapshot

Revenue
TTM
$274.5M
Gross Margin
TTM
94.82%
Net Income
TTM
$153.6M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
2128.05%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$997.3M
Cash
2026 Q1
P/E
TTM
41.27
Free Cash Flow
TTM
$123.1M

Stock Price

Loading...
Market Cap: $6.3378 Billion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support